Otoprotective Effect of 2,3,4',5-Tetrahydroxystilbene-2--β-d-Glucoside on Gentamicin-Induced Apoptosis in Mouse Cochlear UB/OC-2 Cells
Overview
Affiliations
Excessive levels of reactive oxygen species (ROS) lead to mitochondrial damage and apoptotic cell death in gentamicin-induced ototoxicity. 2,3,4',5-Tetrahydroxystilbene-2--β-d-glucoside (THSG), a bioactive constituent, isolated from Thunb., exhibits numerous biological benefits in treating aging-related diseases by suppressing oxidative damage. However, its protective effect on gentamicin-induced ototoxicity remains unexplored. Therefore, here, we aimed to investigate the otoprotective effect of THSG on gentamicin-induced apoptosis in mouse cochlear UB/OC-2 cells. We evaluated the effect of gentamicin and THSG on the ROS level, superoxide dismutase (SOD) activity, mitochondrial membrane potential, nuclear condensation, and lactate dehydrogenase (LDH) release, and the expression of apoptosis-related proteins was assessed to understand the molecular mechanisms underlying its preventive effects. The findings demonstrated that gentamicin increased ROS generation, LDH release, and promoted apoptotic cell death in UB/OC-2 cells. However, THSG treatment reversed these effects by suppressing ROS production and downregulating the mitochondrial-dependent apoptotic pathway. Additionally, it increased the SOD activity, decreased the expression of apoptosis-related proteins, alleviated the levels of the apoptotic cells, and impaired cytotoxicity. To the best of our knowledge, this is the first study to demonstrate that THSG could be a potential therapeutic option to attenuate gentamicin-induced ototoxicity.
Huang T, Chen C, Chen L, Lan Y, Huang T, Choo K Front Pharmacol. 2022; 13:997100.
PMID: 36267283 PMC: 9577370. DOI: 10.3389/fphar.2022.997100.
Lee M, Waldhaus J Mol Cell Neurosci. 2022; 120:103736.
PMID: 35577314 PMC: 9551661. DOI: 10.1016/j.mcn.2022.103736.
Wen Y, Lin H, Lin J, Tseng G, Hwang C, Lin C Int J Mol Med. 2022; 49(5).
PMID: 35348190 PMC: 8989425. DOI: 10.3892/ijmm.2022.5127.
Wang C, Dai S, Gong L, Fu K, Ma C, Liu Y Front Pharmacol. 2022; 12:791214.
PMID: 35069206 PMC: 8769241. DOI: 10.3389/fphar.2021.791214.